Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Want to see AU:IBX full AI Analyst Report?
IBX Stock Chart & Stats
AU$0.03
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.03
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume347.18K
Average Volume (3M)16.05M
Market Cap
AU$8.83M
Enterprise ValueAU$4.47M
Total Cash (Recent Filing)AU$1.85M
Total Debt (Recent Filing)AU$2.56M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary MagSense PlatformImagion’s MagSense platform is a differentiated, proprietary diagnostic approach using magnetic nanoparticles for early cancer detection. Its specialized tech and focus on clinical validation create a structural capability that, if clinically and regulatorily validated, can form a durable competitive moat in diagnostic imaging.
Reduced Cash Burn In 2025A tangible reduction in cash burn in 2025 versus 2024 improves runway and lowers immediate funding pressure. Sustained expense discipline or milestone-driven cost improvements provide lasting benefit by reducing execution risk and extending time to achieve clinical/regulatory milestones without near-term dilution.
Lean Operating StructureA very small headcount suggests a lean cost structure and capital efficiency typical for early-stage diagnostics firms. This enables focused R&D spending and slower cash depletion per milestone, which can be a durable advantage while the business advances clinical validation prior to scaling commercial operations.
Bears Say
Zero Revenue In 2025Reporting zero revenue in 2025 indicates no current commercial traction, leaving the company wholly dependent on financing to sustain operations. Over the medium term this elevates funding and execution risk, constrains reinvestment capacity, and undermines validation of market demand for its diagnostics.
Consistent Negative Cash FlowPersistent negative operating and free cash flow, with ~4.0M burned in 2025, signals ongoing capital dependence. Structurally weak cash generation increases likelihood of future equity or debt raises, dilutes existing shareholders, and can delay or compromise sustained investment required for clinical trials and regulatory approvals.
Negative Equity And Meaningful DebtNegative shareholders' equity combined with non-trivial debt levels undermines solvency metrics and financial flexibility. This structural balance-sheet weakness can restrict access to favorable financing, raise refinancing risk, and increase the probability of dilutive capital raises or restructuring to fund ongoing development.
Imagion Biosystems Ltd. News
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$8.83M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 121 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 490,590,240 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imagion Biosystems Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IBX Sentiment 90%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
142.99%
Trailing 12-Months
Asset Growth
-27.09%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---